Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer.

Autor:	Horne A; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Radiation Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: ashley.horne3@nhs.net., Harada K; Department of Radiation Oncology, Showa University Northern Yokohama Hospital, Tsuzuki-ku, Yokohama, Kanagawa, Japan., Brown KD; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Research and Innovation, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom., Chua KLM; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore., McDonald F; Royal Marsden Hospital, London, UK., Price G; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom., Putora PM; Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Department of Radiation Oncology, Inselspital, University of Bern, Bern, Switzerland., Rothwell DG; CR-UK National Biomarker Centre, University of Manchester, Manchester, United Kingdom., Faivre-Finn C; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Radiation Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Aug; Vol. 19 (8), pp. 1164-1185. Date of Electronic Publication: 2024 Apr 12.
DOI:	10.1016/j.jtho.2024.04.006
Abstrakt:	Owing to major advances in the field of radiation oncology, patients with lung cancer can now receive technically individualized radiotherapy treatments. Nevertheless, in the era of precision oncology, radiotherapy-based treatment selection needs to be improved as many patients do not benefit or are not offered optimum therapies. Cost-effective robust biomarkers can address this knowledge gap and lead to individuals being offered more bespoke treatments leading to improved outcome. This narrative review discusses some of the current achievements and challenges in the realization of personalized radiotherapy delivery in patients with lung cancer. Competing Interests: Disclosure Dr. Brown reports receiving grants from CRUK Lung Cancer Centre of Excellence (institutional award). Dr. Chua reports receiving grants from the National Medical Research Council Singapore Clinician Scientist; an individual research grant from New Investigator Grant (NMRC/CS-IRG-NIG/CNIG20nov-0029); support from the Duke-NUS Medical School Khoo Pilot Award (collaborative); payment or honoraria for lectures from Varian Medical Systems and PeerVoice; support for attending meetings from Varian Medical Systems; and having participation on data safety monitoring board from AstraZeneca, Regeneron, Roche, Seagen, Merck Sharp & Dohme, Takeda. Dr. McDonald reports receiving consulting fees, payment, or honoraria for lectures from AstraZeneca. Dr. Price reports being supported by Cancer Research UK RadNET Manchester, NIHR Manchester Biomedial Research Centre, and National Institute of Health Research. Prof. Faivre-Finn reports receiving consulting fees and payment or honoraria for lectures (to the institution) and having participation on data safety monitoring (to the institution) from AstraZeneca. The remaining authors declare no conflicts of interest. (Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu